September 11, 2007 - CellCyte Genetics Corp. has entered into a collaborative research agreement with physician scientists at the Cleveland Clinic Foundation to investigate the presence and regulation of heart receptors involved in stem cell trafficking in normal and diseased human hearts, using CellCyte's proprietary compounds, with the goal of increasing volumes of stem cells delivered.
CellCyte Genetics is developing stem cell enabling therapeutic products designed to allow more efficient delivery and significantly increased retention of adult stem cells to diseased organs, such as the heart. The goal of this therapy is to increase the number of stem cells delivered to a damaged organ, thereby increasing organ healing and functional restoration. The Company's first product in development, CCG-TH30, is designed to send autologous bone-marrow-derived (adult) stem cells to the heart of patients after a heart attack. In preclinical models, CCG-TH30 has been shown to increase the retention of stem cells up to as much as 80 percent compared to conventional methods, which achieve only up to about 7 percent. Importantly, CellCyte’s product can be delivered intravenously through the patients’ circulatory system without an invasive procedure.
The lead investigators of the project at Cleveland Clinic Foundation are Dr. Wilson Tang M.D. and Dr. Sathyamangla Prasad Ph.D., both accomplished and renowned scientists in the field of cardiac biology. Dr. Tang is also a physician and key opinion leader in cardiac medicine.
The Cleveland Clinic Foundation scientists will analyze heart tissue samples of heart failure patients for the presence of surface receptors that are hypothesized to play an important role in the interaction of stem cells with the heart. These studies are expected to provide valuable novel information that will increase the understanding of cardiac regeneration and will thereby support the discovery and development of novel stem cell therapeutics for the heart. Work on the project is expected to start in October 2007.
For more information: www.clevelandclinic.org and www.cellcyte.com
November 19, 2021 
